Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Operating Leases: 2023-2024

Historic Operating Leases for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $4.8 million.

  • Contineum Therapeutics' Operating Leases was N/A to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year change of. This contributed to the annual value of $4.8 million for FY2024, which is 4350.93% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Operating Leases of $4.8 million as of FY2024, which was up 4,350.93% from $108,000 recorded in FY2023.
  • In the past 5 years, Contineum Therapeutics' Operating Leases ranged from a high of $4.8 million in FY2024 and a low of $108,000 during FY2023.
  • Its 2-year average for Operating Leases is $2.5 million, with a median of $2.5 million in 2023.
  • Data for Contineum Therapeutics' Operating Leases shows a peak YoY skyrocketed of 4,350.93% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Contineum Therapeutics' Operating Leases stood at $108,000 in 2023, then surged by 4,350.93% to $4.8 million in 2024.